teneligliptin

Teneligliptin hydrobromide (MP-513 (hydrobromide)) is a novel dipeptidyl peptidase 4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus with hypoglycemic activity for the study of obesity and diabetes.

Teneligliptin (MP-513) is a novel dipeptidyl peptidase 4 (DPP IV) inhibitor for the treatment of type 2 diabetes mellitus with hypoglycemic activity for the study of obesity and diabetes.

Teneligliptin-D8 is a potent, orally available, competitive, and long-lasting inhibitor of DPP-4.

Teneligliptin hydrobromide hydrate is a potent, competitive, and long-lasting DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC 50 s of approximately 1 nM [1].

Teneligliptin impurity 11 is a pharmaceutical intermediate used in the synthesis of various active compounds.

(2S,4R)-Teneligliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4). It increases the concentration of active glucagon-like peptide-1 (GLP-1) in plasma, which in turn stimulates insulin secretion when blood glucose levels are elevated, thereby exhibiting hypoglycemic effects. (2S,4R)-Teneligliptin is a promising candidate for research in type 2 diabetes.